Zovirax 800 mg Dispersible Tablets

  • Name:

    Zovirax 800 mg Dispersible Tablets

  • Company:
    info
  • Active Ingredients:

    Aciclovir

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/09/15

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 24/8/2017
print

Print ViewKeyword Search SmPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Zinnat 250mg/5ml Granules for Oral Suspension. Active Ingredients Cefuroxime Axetil
Medicine Name Zinnat 500mg Film-Coated Tablets Active Ingredients Cefuroxime Axetil
Medicine Name Zovirax 200 mg Dispersible Tablets Active Ingredients Aciclovir
Medicine Name Zovirax 200 mg/5 mL Oral Suspension Active Ingredients Aciclovir
Medicine Name Zovirax 5% w/w Cream Active Ingredients Aciclovir
Medicine Name Zovirax 800 mg Dispersible Tablets Active Ingredients Aciclovir
Medicine Name Zovirax Double Strength Suspension Active Ingredients Aciclovir
Medicine Name Zovirax IV 250mg Active Ingredients Aciclovir sodium
Medicine Name Zovirax® 30 mg/g Eye Ointment Active Ingredients Aciclovir
Medicine Name Zyban 150 mg prolonged release tablets Active Ingredients Bupropion Hydrochloride
126 - 135 of 135 items.Total: 6 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 August 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 24 August 2017 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC updates:
Section 6.5 - Update to foil blister pack details
Section 10 - Update to Date of Revision of the text

Updated on 21 September 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 21 September 2015 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Minor editorial updates to following sections: 3, 4.3, 4.6, 5.1, 5.2, 5.3, 6.6

Section 4.2 – Update to Dosage for Infants and Children, Addition regarding Administration, Minor editorial update

Section 4.8 – Minor editorial update, Addition of ADR reporting details

Updated on 21 September 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to dosage and administration
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 21 July 2015 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to MA holder contact details

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to MA holder contact details - Address change

Updated on 20 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 8 August 2014 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.2  additional information

Updated on 11 October 2012 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to:

 

Section 4.3  - Contraindications,

Section 4.4  - Special warnings and precautions for use,

Section 4.6  - Pregnancy and lactation,

Section 5.3  - Preclinical safety data

Updated on 5 October 2012 PIL

Reasons for updating

  • Change due to harmonisation of PIL

Updated on 18 November 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 2 December 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 10 September 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.2 Posology and method of administration

Under the subheading ‘Dosage in the elderly’ updated the wording to read:

The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (see Dosage in renal impairment below). Adequate hydration should be maintained.

 

Under the subheading ‘Dosage in renal impairment’ added the following warning:

Caution is advised when administering aciclovir to patients with impaired renal function. Adequate hydration should be maintained.

 

4.4 Special warnings and precautions for use

Under the new subheading Use in patients with renal impairment and in elderly patients’ added the following warning:

Aciclovir is eliminated by renal clearance, therefore the dose must be adjusted in patients with renal impairment (see section 4.2). Elderly patients are likely to have reduced renal function and therefore the need for dose adjustment must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8).

 

4.8 Undesirable Effects

Regarding the adverse events listed under Psychiatric and nervous system disorders’, updated the wording to read:

The above events are generally reversible and usually reported in patients with renal impairment, or with other predisposing factors (see section 4.4).

Updated on 21 January 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Summary of changes due to the approval of the Renewal on 23/10/2009

 

Please note that the name change to the SPC and PL described below must be made also to the medicines.ie entry for this product, currently listed as ‘Zovirax Dispersible Tablets 800 mg’

 

 

SPC UPDATES

 

Section 1 NAME OF THE MEDICINAL PRODUCT

Changed from Zovirax Dispersible Tablets 800mg to (i.e. name, strength, dosage form):

Zovirax 800 mg Dispersible Tablets

 

Section 6.4 Special precautions for storage

Included reason for keeping blisters in the outer carton, i.e.:

‘in order to protect from light and moisture.’

 

Section 6.5 Nature and contents of container

Updated the description of the pack, i.e. that one tablet is included in each blister and that each pack of 35 tablets contains 7 blister strips.

Updated on 18 January 2010 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to storage instructions
  • Change to how the medicine works

Updated on 27 April 2009 PIL

Reasons for updating

  • Change to side-effects

Updated on 27 March 2009 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8: Addition of renal pain as a very rare undesirable effect with the following statement added: 'Renal pain may be associated with renal failure'.

Updated on 5 September 2008 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 5 September 2008 PIL

Reasons for updating

  • PIL re-instated

Updated on 14 June 2007 SmPC

Reasons for updating

  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

5.3       Preclinical safety data

 

There is no information on the effect of aciclovir oral formulations or i.v. for infusion on human female fertility. In a study of 20 male patients with normal sperm count, oral aciclovir administered at doses of up to 1g per day for up to six months has been shown to have no clinically significant effect on sperm count, motility or morphology.

 

NON-CLINICAL INFORMATION

      Mutagenicity

The results of a wide range of mutagenicity tests in vitro and in vivo indicate that acyclovir does not is unlikely to pose a genetic risk to man.

 

      Carcinogenicity

Aciclovir was not found to be carcinogenic in long-term studies in the rat and the mouse.

 

      Fertility

Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at systemic doses of aciclovir greatly in excess of those employed therapeutically. Two-generation studies in mice did not reveal any effect of (orally administered) aciclovir on fertility.

Updated on 1 September 2006 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 August 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 7 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)